Human Study on Synaptopodin and Disability Progression in Progressive Multiple Sclerosis
A study found that a higher level of synaptopodin in neuronal-enriched extracellular vesicles (NEVs) is linked to a lower risk of confirmed disability progression in progressive multiple sclerosis (PMS) patients, showing a 32% reduction at baseline and a 57% reduction in secondary PMS. Additionally, changes in NEV synaptopodin over time correlated with disability worsening.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
Identifying NEV synaptopodin as a potential biomarker for tracking disability progression in PMS may aid in understanding the disease and monitoring its course, particularly for secondary progressive forms.
What this does not prove
The findings indicate an association, not a causal relationship, and the study is based on observational data without peer review, thus requiring further validation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 452 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-09
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- HR 0.71 for NEV synaptopodin vs NfL HR 1.12, p=0.007 vs 0.22; HR 0.58 for NEV synaptopodin vs NfL HR 1.10, p=0.003 vs 0.50
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- NEV synaptopodin; NfL
- Safety
- Not reported
Original sources
- Primary evidenceA Blood-Based Synaptic Biomarker in Neuronally-Enriched Extracellular Vesicles Predicts Disability Progression in Progressive Multiple Sclerosis. ↗DOI: 10.64898/2026.10.07.26364982
Supporting passages (9)
limitationsTitle: A Blood-Based Synaptic Biomarker in Neuronally-Enriched Extracellular Vesicles Predicts Disability Progression in Progressive Multiple Sclerosis.
sample sizeWe measured synaptopodin, a postsynaptic protein, in neuronal-enriched extracellular vesicles (NEVs) across two independent cohorts: the SPRINT-MS trial (n=184) and a real-world validation cohort (n=268).
primary endpointNEV synaptopodin, but not NfL, was associated with confirmed disability progression in PMS participants with both biomarkers measured (HR 0.71 vs 1.12, p=0.007 vs 0.22 for NEV synaptopodin and NfL, respectively) and SPMS (HR 0.58 vs 1.10, p=0.003 vs 0.50).
findingsA one SD increase in baseline synaptopodin was associated with ∼32% lower risk of confirmed disability progression in PMS (p=0.011), with the strongest effect in secondary PMS (SPMS) (∼57% lower odds, p=0.019).
biomarkersThese findings identify NEV synaptopodin as a prognostic and longitudinal, blood biomarker of synaptic integrity in PMS, particularly SPMS, complementing NfL.
effect sizeNEV synaptopodin, but not NfL, was associated with confirmed disability progression in PMS participants with both biomarkers measured (HR 0.71 vs 1.12, p=0.007 vs 0.22 for NEV synaptopodin and NfL, respectively) and SPMS (HR 0.58 vs 1.10, p=0.003 vs 0.50).
publication datePublication date: 2026-10-09
peer reviewedPublication types: Journal Article; Preprint
subjectsNEV synaptopodin, but not NfL, was associated with confirmed disability progression in PMS participants with both biomarkers measured (HR 0.71 vs 1.12, p=0.007 vs 0.22 for NEV synaptopodin and NfL, respectively) and SPMS (HR 0.58 vs 1.10, p=0.003 vs 0.50).
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.